2-[[3-hexadecanoyloxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 2-[[3-hexadecanoyloxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
• 化学式: C42H81NO8P+
• 分子量: 759.1
• InChiKey: JLPULHDHAOZNQI-AKMCNLDWSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  13
• 重原子数：
  52
• 可旋转键数：
  40
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] SMALL MOLECULE FERROPTOSIS INDUCERS<br/>[FR] INDUCTEURS DE FERROPTOSE À PETITES MOLÉCULES
  申请人：UNIV COLUMBIA

  公开号：WO2018118711A1

  公开（公告）日：2018-06-28

  The present invention provides, inter alia, a compound according to formula (I). Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for regulating GPX4 in a cell and methods for inducing ferroptosis in a cell.

  本发明提供了一种符合公式（I）的化合物，此外还提供了含有药学上可接受载体和本发明中化合物的组合物。进一步提供了在细胞中调节GPX4的方法以及在细胞中诱导铁死亡的方法。
• Small molecule ferroptosis inducers
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US10947188B2

  公开（公告）日：2021-03-16

  The present invention provides, inter alia, a compound according to formula (I): Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for regulating GPX4 in a cell and methods for inducing ferroptosis in a cell.

  本发明特别提供了一种符合式 (I) 的化合物： 还提供了含有药学上可接受的载体和根据本发明的化合物的组合物。此外，还提供了调节细胞中 GPX4 的方法和诱导细胞中铁细胞凋亡的方法。
• TOPICAL DELIVERY OF THERAPEUTIC AGENTS COMPRISING CELL-PENETRATING PEPTIDES FOR USE FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES
  申请人：Roizman, Keith

  公开号：EP3654941A1

  公开（公告）日：2020-05-27
• SMALL MOLECULE FERROPTOSIS INDUCERS
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US20190315681A1

  公开（公告）日：2019-10-17

  The present invention provides, inter alia, a compound according to formula (I): Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for regulating GPX4 in a cell and methods for inducing ferroptosis in a cell.
• [EN] TOPICAL DELIVERY OF THERAPEUTIC AGENTS COMPRISING CELL-PENETRATING PEPTIDES FOR USE FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES<br/>[FR] ADMINISTRATION TOPIQUE D'AGENTS THÉRAPEUTIQUES COMPRENANT DES PEPTIDES DE PÉNÉTRATION CELLULAIRE, DESTINÉS À ÊTRE UTILISÉS POUR LE TRAITEMENT DE LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE ET AUTRES MALADIES OCULAIRES
  申请人：ROIZMAN KEITH

  公开号：WO2019018350A1

  公开（公告）日：2019-01-24

  The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders. One or more therapeutic agents can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (including non-central GA and central GA) and neovascularization (including types 1, 2 and 3 NV). In some embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent, an antioxidant, an anti-inflammatory agent, a complement inhibitor, a neuroprotector or an anti-angiogenic agent, or any combination thereof. In certain embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent (e.g., an apolipoprotein mimetic or/and a statin). In some embodiments, the one or more therapeutic agents are mixed with, non-covalently associated with or covalently bonded to a cell-penetrating peptide (CPP), encapsulated in CPP-conjugated nanoparticles, micelles or liposomes, or modified (e.g., stapled, prenylated, lipidated or coupled to a small-molecule ?-helix mimic) to acquire membrane-translocating ability. In certain embodiments, the one or more therapeutic agents are administered by eye drop.